TYPE 2 diabetes, more commonly seen in adults, is rising among chil­dren in Trinidad and Tobago.Increasingly unheal­thy ...

Abbott rolled out its first over-the-counter glucose sensor in the U.S. on Thursday, just over one week after Dexcom began selling its competing product. The device, called Lingo, is intended to be ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

Piper Sandler initiated coverage on Abbott Laboratories (NYSE: ABT) with an "overweight" rating and a price target of $131 ...

Continuous Glucose Monitoring (CGM) Systems Market The increasing incidence of diabetes and the detection of patient's blood glucose levels are raising the demand for continuous global monitoring ...

Abbott (NYSE:ABT) faces a proposed class action lawsuit related to alleged tracking tools used with its FreeStyle Libre ...

DUBLIN, Sept. 18, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today ...

If a patient receives a continuous glucose monitor device through their medical benefit, they may be more adherent and may ...

Real-world data showed reductions in healthcare resource utilization and improved glycemic control over 1 year with ...

Leveraging rapid technological advances for human health is a global trend, driving the rise of biomedical engineering ...

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the launch of the third season of Dexcom U, the company's ...

Eversense 365 is said to be the world's first one-year CGM system, offering a new long-term solution for diabetes management.